Preference as a precautionary healthcare procedure for immunocompromised children continue to bolster the growth of pediatric neuroblastoma treatment market. reveals Fact.MR. High incidences of neuroblastoma in children below the age of one year and high burden of the ailment remainsource https://www.openpr.com/news/2237398/pediatric-neuroblastoma-treatment-market-revenue